143 results match your criteria ACR open rheumatology[Journal]


Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

ACR Open Rheumatol 2020 Jul 6. Epub 2020 Jul 6.

University of Pennsylvania, Philadelphia, Pennsylvania.

Objective: To compare the characteristics of patients with axial spondyloarthritis (axSpA) who had enthesitis versus those without enthesitis.

Methods: This study included adult patients with axSpA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry (March 2013 to August 2018). Enthesitis was assessed at enrollment via the Spondyloarthritis Research Consortium of Canada Enthesitis Index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11154DOI Listing

A Standardized, Pragmatic Approach to Knee Ultrasound for Clinical Research in Osteoarthritis: The Johnston County Osteoarthritis Project.

ACR Open Rheumatol 2020 Jun 29. Epub 2020 Jun 29.

University of North Carolina at Chapel Hill.

Objective: This study sought to develop and employ a comprehensive and standardized ultrasound (US) protocol and scoring atlas for the evaluation of features relevant to knee osteoarthritis (KOA) in a community-based cohort in the United States, with the goals of demonstrating feasibility, reliability, and validity.

Methods: We utilized data from the fourth follow-up (2016-2018) of the Johnston County OA Project, which includes individuals with (~50%) and without radiographic KOA. All participants underwent standardized knee radiography and completed standard questionnaires including the Knee Injury and Osteoarthritis Outcome Score (KOOS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11159DOI Listing

Racial Disparities in Medication Adherence between African American and Caucasian Patients With Systemic Lupus Erythematosus and Their Associated Factors.

ACR Open Rheumatol 2020 Jun 25. Epub 2020 Jun 25.

Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, USA.

Objective: Medication nonadherence is more common in African Americans compared with Caucasians. We examined the racial adherence gaps among patients with systemic lupus erythematosus (SLE) and explored factors associated with nonadherence.

Methods: Cross-sectional data were obtained from consecutive patients prescribed SLE medications seen at an academic lupus clinic between August 2018 and February 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11160DOI Listing

Expanded Autoantibody Profiles for Subsetting of Native American, African American, and European American Patients With Systemic Lupus Erythematosus.

ACR Open Rheumatol 2020 Jun 22. Epub 2020 Jun 22.

Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City.

Objective: Many Native American (NA) patients with systemic lupus erythematosus (SLE) do not exhibit the classical SLE autoantibody profiles of European American (EA) and African American (AA) patients with SLE. The poorer SLE disease outcomes noted in NA patients highlights a need for more equitable diagnostic and prognostic tools for NA patients with SLE. The objective was to identify informative autoantibody profiles for NA, AA, and EA patients with SLE using an expanded set of autoantigens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11149DOI Listing

Determination of Rheumatoid Arthritis Incidence and Prevalence in Alberta Using Administrative Health Data.

ACR Open Rheumatol 2020 Jun 22. Epub 2020 Jun 22.

University of Calgary, Alberta, Canada.

Objective: The objective of the study was to estimate the incidence and prevalence of rheumatoid arthritis (RA) in Alberta using administrative health data.

Methods: We identified RA cases in patients 16 years and older by applying a national case definition to linked administrative health data (ie, hospital discharge abstract records, physician claims, and health insurance registry records) using a unique personal identifier. Incidence and prevalence are reported for the 2015-2016 fiscal year and a trend analysis from 2011-2012 to 2015-2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11158DOI Listing

Recombinant Soluble TNF-α Receptor Fusion Protein Therapy Reduces Insulin Resistance in Non-Diabetic Active Rheumatoid Arthritis Patients.

ACR Open Rheumatol 2020 Jun 12. Epub 2020 Jun 12.

National Cheng Kung University Hospital, Tainan, Taiwan.

Objective: Current evidence highlights a link between insulin resistance (IR) and disease activity in rheumatoid arthritis (RA), suggesting that insulin sensitivity can be improved by treating patients with TNF-α blockers. Although reduced IR has been shown in RA patients who receive monoclonal antibody treatment, the efficacy remains to be elucidated when using recombinant soluble receptor fusion proteins. In particular, etanercept (ETA) is capable of blocking lymphotoxin-α, a cytokine-related to IR-associated disease status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11157DOI Listing

The Follistatin-like Protein 1 Pathway Is Important for Maintaining Healthy Articular Cartilage.

ACR Open Rheumatol 2020 Jun 12. Epub 2020 Jun 12.

University of Iowa Carver College of Medicine, Iowa City.

Objective: We sought to determine whether follistatin-like protein 1 (FSTL1), a protein produced by articular chondrocytes, promotes healthy articular cartilage and prevents chondrocytes from undergoing terminal differentiation to hypertrophic cells.

Methods: In vitro experiments were performed with immortalized human articular chondrocytes. The cells were transduced with a lentivirus encoding human FSTL1 small hairpin RNA or with an adenovirus encoding FSTL1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11155DOI Listing

Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey.

ACR Open Rheumatol 2020 Jun 9. Epub 2020 Jun 9.

Cedars-Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles.

Objective: The number of therapies for axial spondyloarthritis (axSpA) is increasing. Thus, it has become more challenging for patients and physicians to navigate the risk-benefit profiles of the various treatment options. In this study, we used conjoint analysis-a form of trade-off analysis that elucidates how people make complex decisions by balancing competing factors-to examine patient decision-making surrounding medication options for axSpA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11151DOI Listing

Impact of a Multifaceted Educational Program to Improve Provider Skills for Lupus Pregnancy Planning and Management: A Mixed-Methods Approach.

ACR Open Rheumatol 2020 Jun 2;2(6):378-387. Epub 2020 Jun 2.

Duke University School of Medicine, Durham, North Carolina.

Objective: To bring recent advances in pregnancy management in lupus to women nationwide, this multidimensional educational intervention sought to equip community rheumatologists with the needed skills, attitudes, and confidence to manage contraceptive decisions and pregnancy planning for women with lupus.

Methods: The program included an in-person didactic, training in use of a comprehensive handout to guide contraception and pregnancy conversations, a simulated clinical experience, and access to an innovative website (www.lupuspregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301872PMC

Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis.

ACR Open Rheumatol 2020 Jun 26;2(6):371-377. Epub 2020 May 26.

Royal Adelaide Hospital and University of Adelaide, Adelaide, South Australia, Australia.

Objective: We aimed to evaluate the associations between response to algorithm-directed treat-to-target conventional synthetic disease-modifying antirheumatic drug therapy and potentially modifiable lifestyle factors, including dietary fish oil supplementation, body mass index (BMI), and smoking history in a rheumatoid arthritis (RA) inception cohort.

Methods: Patients with RA with a duration of less than 12 months were reviewed every 3 to 6 weeks to adjust therapy according to disease response. All patients received advice to take fish oil supplements, and omega-3 status was measured as plasma levels of eicosapentaenoic acid (EPA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11132DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301874PMC

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II.

ACR Open Rheumatol 2020 Jun 20;2(6):362-370. Epub 2020 May 20.

University of Michigan Medical School, Ann Arbor.

Objective: Our objective was to determine if treatment with cyclophosphamide (CYC) and mycophenolate mofetil (MMF) improves patient-reported outcomes (PROs) among patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).

Methods: This study examined PROs in patients with SSc-ILD (N = 142) who participated in the Scleroderma Lung Study II, a randomized controlled trial comparing MMF for 2 years with oral CYC for 1 year followed by 1 year of a placebo. Joint models were created to evaluate the course of PROs over 2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301868PMC

Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients.

ACR Open Rheumatol 2020 Jun 15;2(6):357-361. Epub 2020 May 15.

Brigham and Women's Hospital Boston, Massachusetts.

Objective: Patients with rheumatoid arthritis (RA) and other systemic rheumatic diseases (SRDs) are at increased risk of developing herpes zoster (HZ). Zoster recombinant adjuvanted (ZRA) is a recombinant vaccine approved by the Food and Drug Administration in 2018. Concern has been raised that the ZRA may trigger disease flares in rheumatology patients who are immunocompromised. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11150DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301873PMC

How to Effectively Support Patients with Rheumatic Conditions Now and Beyond COVID-19.

ACR Open Rheumatol 2020 May 13. Epub 2020 May 13.

Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.

May 2020, the COVID-19 pandemic continues to unfold. Governments are investing in public health, clinical and research efforts to avoid the spread of the SARS-CoV-2 virus, reduce the number of deaths and prevent the collapse of health care systems. However, this pandemic will have unprecedented consequences for people who live with chronic conditions for the months and even years to come without coordinated actions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272921PMC

Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms.

ACR Open Rheumatol 2020 Jun 11;2(6):344-356. Epub 2020 May 11.

Karolinska Institutet, Stockholm, Sweden.

Objective: Immunoglobulin M antibodies against phosphorylcholine (anti-PCs) may be protective in atherosclerosis, cardiovascular disease (CVD), and systemic lupus erythematosus (SLE). We study immunoglobulin G1 (IgG1) and immunoglobulin G2 (IgG2) anti-PCs, with a focus on atherosclerosis and SLE.

Methods: We determined anti-PCs by using the enzyme-linked immunosorbent assay in 116 patients with SLE and 110 age- and sex-matched controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301871PMC

Higher Disability in Women Than Men Scheduled for Total Knee Arthroplasty for Degenerative Osteoarthritis: A Cross-Sectional Analysis From India.

ACR Open Rheumatol 2020 Jun 9;2(6):309-319. Epub 2020 May 9.

Deakin University, Victoria, Geelong, Australia.

Objective: Higher level impairments and activity limitation among those scheduled for total knee arthroplasty (TKA) is known. Sex differences in participation restriction which is the final domain of disablement pathway is not known. No data from developing countries exist on sex differences in disability levels at the time of TKA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301870PMC

Estimation of Minimally Important Differences and Patient Acceptable Symptom State Scores for the Patient-Reported Outcomes Measurement Information System Pain Interference Short Form in Rheumatoid Arthritis.

ACR Open Rheumatol 2020 Jun 9;2(6):320-329. Epub 2020 May 9.

FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas, and University of Nebraska Medical Center, Omaha.

Objective: Studies have supported the validity of the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference (PI) scale in rheumatoid arthritis (RA). Here, we characterize minimally important differences (MIDs) and patient acceptable symptom state (PASS) values.

Methods: PROMIS PI scores were collected in four periods at 6-month intervals from patients with RA (n > 3200 per period). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301876PMC

Probiotic Use and Psoriatic Arthritis Disease Activity.

ACR Open Rheumatol 2020 Jun 9;2(6):330-334. Epub 2020 May 9.

University of Nebraska Medical Center, Omaha, Nebraska.

Objective: Probiotics have been hypothesized to mediate inflammation through gut microbiome modulation. Spondyloarthropathies have subclinical gut inflammation associated with inflammatory disease that may benefit from probiotic use. We aimed to evaluate associations between probiotic use and patient-reported outcomes in patients with psoriatic arthritis (PsA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301869PMC

A Proposal to Standardize Low Disease Activity Criteria in Rheumatoid Arthritis Based on the Outcome Measures in Rheumatology Minimal Disease Activity Definition.

ACR Open Rheumatol 2020 May 3;2(5):301-306. Epub 2020 May 3.

Tokyo National Hospital, National Hospital Organization, Tokyo, Japan.

Objective: We aimed to standardize the definition of low disease activity in rheumatoid arthritis (RA) using the Outcome Measures in Rheumatology (OMERACT) group's proposed definition of minimal disease activity.

Method: Based on a nationwide RA database, we proposed new Boolean low disease activity criteria using OMERACT's core set definition of minimal disease activity that requires the fulfillment of at least five of the following seven core set measures: a pain score of 2 or less, a swollen joint count (SJC28) of 1 or fewer, a tender joint count of 1 or fewer, a Health Assessment Questionnaire score of 0.5 or less, a Physician's Global Assessment score of 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231521PMC

Medical Cannabis Use by Rheumatology Patients Following Recreational Legalization: A Prospective Observational Study of 1000 Patients in Canada.

ACR Open Rheumatol 2020 May 30;2(5):286-293. Epub 2020 Apr 30.

Klinikum Saarbrücken, Saarbrücken, Germany, and Technische Universität München, München, Germany.

Objective: Recreational legalization of cannabis may influence the medical use by patients. When only medical access was legally available in Canada, 4.3% of rheumatology patients reported use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231516PMC

Differences between acute and chronic disease: comment on the article by Holman.

ACR Open Rheumatol 2020 May 30;2(5):300. Epub 2020 Apr 30.

Hospital for Special Surgery, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231520PMC

Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.

ACR Open Rheumatol 2020 May 30;2(5):294-299. Epub 2020 Apr 30.

Oregon Health & Science University and Legacy Devers Eye Institute, Portland.

Objective: The objective of this study was to report the incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis (AS) in a pooled analysis of three phase 3 trials (MEASURE 1-3 [ClinicalTrials.gov identifiers NCT01358175, NCT01649375, NCT02008916]).

Methods: Analysis included pooled patient-level data from all patients (N = 794) who received any dose (one or more) of secukinumab up to the last patient attending the week 156 study visit in MEASURE 1 and up to the week 156 visit in MEASURE 2 and the week 104 visit in MEASURE 3 for each patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231512PMC

External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-Inflammatory Drug Users: Real-World Application.

ACR Open Rheumatol 2020 May 21;2(5):269-275. Epub 2020 Apr 21.

Corrona Research Foundation.

Objective: We previously derived and validated a risk score for major nonsteroidal anti-inflammatory drug (NSAID) toxicity over 1 year among NSAID users in a randomized controlled trial. This work was extended to examine the risk score's performance in an external population using real-world data.

Methods: Patients enrolled in the Corrona Rheumatoid Arthritis (RA) Registry were included if they initiated use of an NSAID. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231515PMC

Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis.

ACR Open Rheumatol 2020 May 21;2(5):261-268. Epub 2020 Apr 21.

Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Objective: Originator intravenous rituximab is an important rheumatology treatment but is costly, and administration requires several hours. Because biosimilar rituximab may cost less and subcutaneous rituximab requires a shorter visit, both may reduce costs and increase treatment capacity (infusions per year).

Methods: We implemented time-driven activity-based costing (TDABC), a method to assess costs and opportunities to increase capacity, throughout the care pathway for 26 patients receiving a total of 30 rituximab infusions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231514PMC

Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis.

ACR Open Rheumatol 2020 May 20;2(5):255-260. Epub 2020 Apr 20.

Albany Medical Center, Albany, New York.

Objective: Patients with rheumatoid arthritis (RA) have higher incidence of cardiovascular diseases (CVDs) compared with age- and sex-matched controls. The objective of our study was to measure the knowledge of patients with RA about the association between their disease and cardiovascular (CV) risk and to measure the frequency of counseling by physicians based on patient report.

Methods: A telephone survey was conducted among patients with RA enrolled in the Consortium of Rheumatology Researchers of North America RA registry to collect data on medical and social history and on knowledge about CVD risk in RA and how they learned about that risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11136DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231519PMC

Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic.

ACR Open Rheumatol 2020 Jun 9;2(6):335-343. Epub 2020 May 9.

University of California, San Francisco.

Objective: Patients with rheumatic diseases such as rheumatoid arthritis (RA) and lupus have increased risk of infection and are treated with medications that may increase this risk yet are also hypothesized to help treat COVID-19. We set out to understand how the COVID-19 pandemic has impacted the lives of these patients in the United States.

Methods: Participants in a US-wide longitudinal observational registry responded to a supplemental COVID-19 questionnaire by e-mail on March 25, 2020, about their symptoms, COVID-19 testing, health care changes, and related experiences during the prior 2 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264613PMC

A Policy to Do Better Next Time: Lessons Learned From the COVID-19 Pandemic.

ACR Open Rheumatol 2020 May 30;2(5):253-254. Epub 2020 Apr 30.

University of California, Berkeley.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231513PMC

Measuring Advanced/Extended Practice Roles in Arthritis and Musculoskeletal Care in Canada.

ACR Open Rheumatol 2020 Apr 11;2(4):242-250. Epub 2020 Apr 11.

Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Objective: Our objective was to characterize Canadian workforce attributes of extended role practitioners (ERPs) in arthritis care.

Methods: We used an exploratory, mixed-methods study that was based on the Canadian Rheumatology Association's Stand Up and Be Counted Rheumatologist Workforce Survey (2015). An anonymous online survey was deployed to groups of non-physician health care professionals across Canada who potentially had post-licensure training in arthritis care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164630PMC

Disease Activity and Anticitrullinated Peptide Antibody Positivity Predict the Worsening of Ventricular Function in Rheumatoid Arthritis.

ACR Open Rheumatol 2020 Apr 8;2(4):232-241. Epub 2020 Apr 8.

University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

Objective: This prospective study was designed to analyze the incidence and the factors associated with impairment in left ventricular systolic function (LVSF) overtime in patients with rheumatoid arthritis (RA) without overt cardiac disease. In particular, we verified the hypothesis that a relationship between worsening of LVSF and markers of RA disease activity exists.

Methods: One hundred forty outpatients with RA without overt heart disease underwent clinical, laboratory, and echocardiographic evaluation at baseline and after 35 (interquartile range [IQR] 23-47) months of follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164632PMC

Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Drugs: A Cohort Study.

ACR Open Rheumatol 2020 Apr 8;2(4):222-231. Epub 2020 Apr 8.

Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Objective: The objective of this study is to compare the risk of incident diabetes mellitus (DM) in patients with rheumatoid arthritis (RA) treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.

Methods: A new-user observational cohort study was conducted using data from a US commercial (Truven MarketScan, 2005-2016) claims database and a public insurance (Medicare, 2010-2014) claims database. Patients with RA who did not have DM were selected into one of eight exposure groups (abatacept, infliximab, adalimumab, golimumab, certolizumab, etanercept, tocilizumab, or tofacitinib) and observed for the outcome of incident DM, defined as a combination of a diagnosis code and initiation of a hypoglycemic treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164631PMC

Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.

ACR Open Rheumatol 2020 May 21;2(5):276-282. Epub 2020 Apr 21.

Regions Hospital, HealthPartners, St. Paul, Minnesota, and University of Minnesota Medical School, Minneapolis.

Objective: The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin-1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis or macrophage activation syndrome (MAS).

Methods: A retrospective chart review of five patients treated at Regions Hospital from 2016 to 2019 was conducted. Demographic, clinical, and laboratory characteristics and outcomes were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231518PMC

Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019.

ACR Open Rheumatol 2020 May 10;2(5):283-285. Epub 2020 May 10.

New York University School of Medicine, New York.

Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) are increasingly recognized as being on a continuum of cytokine storm syndromes, with different initiating pathways culminating in cytotoxic dysfunction and uncontrolled activation and proliferation of T lymphocytes and macrophages. The activated immune cells produce large amounts of proinflammatory cytokines, including interleukin 1β (IL)-1β. Management depends on the recognized diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231517PMC

The Role of Environmental Distractions in the Experience of Fibrofog in Real-World Settings.

ACR Open Rheumatol 2020 Apr 1;2(4):214-221. Epub 2020 Apr 1.

Pennsylvania State University, University Park, Pennsylvania.

Objective: Perceived cognitive dysfunction in people with fibromyalgia (FM), "fibrofog," is commonly reported and has been demonstrated in neurocognitive testing. Distractibility and inattention have been implicated as potential contributors to fibrofog, but the role of environmental distractions has not been explored. In this study, ambulatory assessment methods were used to examine whether FM is related to more environmental distractions and to examine the impact of distractions on subjective and objective cognitive functioning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164629PMC

How Do Patients With Axial Spondyloarthritis Experience High-Intensity Exercise?

ACR Open Rheumatol 2020 Apr 1;2(4):207-213. Epub 2020 Apr 1.

University of Gothenburg, Gothenburg, Sweden.

Objective: In a few studies, high-intensity exercise has displayed beneficial effects on cardiovascular health among patients with rheumatic diseases, yet the high-intensity exercise mode is still not fully accepted among health care professionals. The aim of this study was to investigate experiences of high-intensity exercise among patients with axial spondyloarthritis.

Methods: Fourteen respondents who had participated in a high-intensity exercise program for 12 weeks were included in this qualitative study with individual semistructured, in-depth interviews. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11128DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164628PMC

Increased Mortality in Asians With Systemic Sclerosis in Northern California.

ACR Open Rheumatol 2020 Apr 21;2(4):197-206. Epub 2020 Mar 21.

Stanford University School of Medicine and Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, California.

Objective: The objective of this study is to evaluate racial/ethnic differences in disease manifestations and survival in a US cohort of patients with systemic sclerosis (SSc), with a focus on Asian patients.

Methods: A retrospective cohort study was conducted among Kaiser Permanente Northern California adults with an incident SSc diagnosis by a rheumatologist from 2007 to 2016, confirmed by a chart review to fulfill 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria. Self-reported race/ethnicity was categorized as non-Hispanic white, Asian, Hispanic, and black. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164633PMC

Modified Disease Activity Score at 3 Months Is a Significant Predictor for Rapid Radiographic Progression at 12 Months Compared With Other Measures in Patients With Rheumatoid Arthritis.

ACR Open Rheumatol 2020 Mar 14;2(3):188-194. Epub 2020 Mar 14.

The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada.

Objective: Progressive rheumatoid arthritis (RA) is responsible for joint damage causing disabilities, but there is no agreement on which disease measures best predict radiographic progression. We aimed to determine which disease activity measures, including the disease activity score, the modified disease activity score in 28 joints with C-reactive protein testing (M-DAS28-CRP), the Clinical Disease Activity Index, and the Health Assessment Questionnaire Disability Index, at baseline and 3 months best predicted rapid radiographic progression (RRP) in patients with early RA.

Methods: Data were used from PREMIER, a 2-year, multicenter, double-blind, active comparator controlled study with methotrexate (MTX)-naïve patients with RA and active disease for less than 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077779PMC

Management of Gout in the United States: A Claims-based Analysis.

ACR Open Rheumatol 2020 Mar 1;2(3):180-187. Epub 2020 Mar 1.

RILITE Research Institute, Charlottesville, Virginia.

Objective: Gout is the most common inflammatory arthritis in the United States. Although numerous guidelines exist for the management of gout, they are not routinely implemented. This study evaluated the real-world practice patterns in gout patients using large administrative claims databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077776PMC

Risk Factor Profiles for Individuals With Diagnosed OA and With Symptoms Indicative of OA: Findings From the Canadian Longitudinal Study on Aging.

ACR Open Rheumatol 2020 Mar 1;2(3):174-179. Epub 2020 Mar 1.

Healthcare & Outcomes Research, Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada and Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Objective: The vast majority of published estimates of osteoarthritis (OA) burden are based on an OA diagnosis. These data are limited, as individuals often do not visit a physician until their symptoms are moderate to severe. This study compared individuals with an OA diagnosis to those with OA joint symptoms but without a diagnosis considering a number of sociodemographic and health characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077769PMC

The Relation of the Chronic Disease Epidemic to the Health Care Crisis.

Authors:
Halsted R Holman

ACR Open Rheumatol 2020 Mar 19;2(3):167-173. Epub 2020 Feb 19.

Stanford University, Palo Alto, California.

Currently, some 50% of the US population has a chronic disease, creating an epidemic, and 86% of health care costs are attributable to chronic disease. The medical profession and its leadership did not recognize or respond appropriately to the rising prevalence of chronic disease. As a consequence, a health care crisis emerged, with inadequate access to care and quality of care together with excessive costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077778PMC

Thyroid Disease in Lupus: An Updated Review.

ACR Open Rheumatol 2020 Feb 6;2(2):74-78. Epub 2020 Jan 6.

Case Western Reserve University at MetroHealth Medical Center, Cleveland, Ohio.

In the following review, we seek to provide an overview of the current understanding of various thyroid manifestations affecting patients with systemic lupus erythematosus (SLE), including topics ranging from thyroid-related complications to SLE in pregnancy. Autoimmune diseases tend to coincide, and an association between thyroid disease and SLE has been reported for more than 50 years. There is no evidence that the coexistence of thyroid disease and lupus alters the disease course or manifestations of either. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011406PMC
February 2020

Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development.

ACR Open Rheumatol 2020 Feb 1;2(2):65-73. Epub 2020 Jan 1.

Brigham and Women's Hospital, Boston, Massachusetts.

Objective: Most patients with rheumatoid arthritis (RA) strive to consolidate their treatment from methotrexate combinations. The objective of this analysis was to identify patients with RA most likely to achieve remission with tocilizumab (TCZ) monotherapy by developing and validating a prediction model and associated remission score.

Methods: We identified four TCZ monotherapy randomized controlled trials in RA and chose two for derivation and two for internal validation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011418PMC
February 2020

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.

ACR Open Rheumatol 2020 Feb 6;2(2):79-83. Epub 2020 Jan 6.

Brigham and Women's Hospital, Boston, MA and Boston VA Medical Center and Harvard Medical School.

Objective: It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility. This study evaluates biosimilar tumor necrosis factor inhibitor (TNFi) utilization across rheumatology practices in the United States and compares whether patients initiating biosimilars remain on these treatments at least as long as new initiators of bio-originators.

Methods: We identified a cohort of patients initiating a TNFi biosimilar between January 2017 and September 2018 from an electronic health record registry containing data from 218 rheumatology practices and over 1 million rheumatology patients in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011419PMC
February 2020

Utility of Coronary Calcium Scoring (CCS) in Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis - A Systematic Review.

ACR Open Rheumatol 2020 Feb 6;2(2):84-91. Epub 2020 Jan 6.

University of Michigan, Ann Arbor.

Objective: To assess the current state of knowledge for the utility of coronary calcium scoring (CCS) in connective tissue disorders (CTDs) as it relates to the presence and quantification of coronary atherosclerosis.

Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a literature search via PubMed, Embase, Scopus, Web of Science Core Collection, CINAHL, and Cochrane Database of Systematic Review retrieved 1019 studies (since database inception on May 7, 2018) from which 121 manuscripts were eligible for review. Inclusion criteria consisted of studies that investigated CCS in adults with respective CTDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011425PMC
February 2020

Brief Report: State-Level Number of Physically Inactive US Adults With Arthritis Who can Improve Their Anxiety and Depression by Exercising.

ACR Open Rheumatol 2020 Feb 6;2(2):92-96. Epub 2020 Jan 6.

University of North Carolina, Chapel Hill.

Objective: Provide state-level estimates of the number of physically inactive adults in the United States with arthritis and other rheumatic and musculoskeletal diseases (RMDs) who could improve their anxiety and depression by exercising.

Methods: Utilizing 1) number-needed-to treat (NNT) data from two prior meta-analyses of randomized controlled trials addressing the effects of exercise on anxiety and depression in adults with arthritis and other RMDs, 2) recent state-level prevalence estimates on arthritis and physical inactivity in adults with arthritis and other RMDs, and 3) state-level 2010 US Census population data, the number of physically inactive adults with arthritis and other RMDs who could improve their anxiety and depression by exercising was estimated.

Results: Across all states and the District of Columbia, the number of adults with arthritis and other RMDs who could improve their anxiety and depression by starting an exercise program was estimated at 3 433 167 (95% confidence interval [CI] = 3 171 000-3 703 522) for anxiety and 2 942 706 (95% CI = 2 718 000-3 174 438) for depression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011451PMC
February 2020

A Clinically and Biologically Based Subclassification of the Idiopathic Inflammatory Myopathies Using Machine Learning.

ACR Open Rheumatol 2020 Mar 10;2(3):158-166. Epub 2020 Feb 10.

Duke University School of Medicine, Durham, North Carolina.

Objective: Published predictive models of disease outcomes in idiopathic inflammatory myopathies (IIMs) are sparse and of limited accuracy due to disease heterogeneity. Computational methods may address this heterogeneity by partitioning patients based on clinical and biological phenotype.

Methods: To identify new patient groups, we applied similarity network fusion (SNF) to clinical and biological data from 168 patients with myositis (64 adult polymyositis [PM], 65 adult dermatomyositis [DM], and 39 juvenile DM [JDM]) in the Rituximab in Myositis trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077789PMC

Exploring the Perceived Impact of the Chronic Disease Self-Management Program on Self-Management Behaviors among African American Women with Lupus: A Qualitative Study.

ACR Open Rheumatol 2020 Mar 9;2(3):147-157. Epub 2020 Feb 9.

Emory University Rollins School of Public Health, Atlanta, Georgia.

Objective: To qualitatively explore the processes through which the Chronic Disease Self-Management Program (CDSMP)-a peer-led, group-based educational intervention for people with chronic conditions-affects self-management behaviors among African American women with systemic lupus erythematosus (SLE).

Methods: Using a longitudinal pre- and postintervention design, we conducted two waves of one-on-one, semistructured interviews with 24 purposefully sampled participants. Wave 1 interviews explored self-management behaviors at baseline; wave 2 interviews focused on changes in these behaviors postintervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077773PMC

Parental Perspectives about Research and Knowledge Translation in Juvenile Idiopathic Arthritis.

ACR Open Rheumatol 2020 Mar 29;2(3):138-146. Epub 2020 Jan 29.

IWK Health Care Centre and Dalhousie University, Halifax, Nova Scotia, Canada.

Objective: To identify barriers and facilitators to the uptake of information from research by parents of children with juvenile idiopathic arthritis (JIA).

Methods: Parents of children with JIA participated in focus group and telephone interviews at four Canadian pediatric rheumatology centers. The semistructured interviews focused on perceptions about JIA research, how new information about JIA was obtained and used, and what information was of most interest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077774PMC

Outreach to Promote Management of Cardiovascular Risk in Primary Care Among Patients With Rheumatoid Arthritis Seen in Rheumatology Practice.

ACR Open Rheumatol 2020 Mar 27;2(3):131-137. Epub 2020 Jan 27.

DuPage Medical Group, Westmont, Illinois.

Objective: Rheumatoid arthritis (RA) confers a 1.5- to 2.0-fold increased risk of cardiovascular disease (CVD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077787PMC

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.

ACR Open Rheumatol 2020 Feb 20;2(2):119-127. Epub 2020 Jan 20.

Novartis Pharma AG, Basel, Switzerland.

Objective: Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years. Here, we report end-of-study 3-year efficacy and safety results of secukinumab 150 and 300 mg from the MEASURE 3 study.

Methods: A total of 226 patients was randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous (s. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011421PMC
February 2020

Universal Health Literacy Precautions Are Associated With a Significant Increase in Medication Adherence in Vulnerable Rheumatology Patients.

ACR Open Rheumatol 2020 Feb 19;2(2):110-118. Epub 2020 Jan 19.

Denver Health and Hospital Authority, University of Colorado Medical School, Denver, Aurora, Colorado.

Objective: Our objective was to determine the impact of the Health Literacy Universal Precautions Toolkit, adapted for rheumatology, on medication adherence, patient satisfaction, and feasibility in all patients; its effect on the clinical disease activity index (CDAI) was studied in a rheumatoid arthritis (RA) subpopulation.

Methods: Data collected during a 6-month prospective quality assurance intervention was compared with data from a prior 6-month period. Interventions included 1) encouraging questions, 2) teach-back communication, and 3) brown-bag medication review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011426PMC
February 2020

Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus.

ACR Open Rheumatol 2020 Jan 4;2(1):53-60. Epub 2019 Dec 4.

University of Nebraska Medical Center, Omaha, and FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas.

Objective: Examinations of Patient-Reported Outcomes Measurement Information System (PROMIS) measures in adult systemic lupus erythematosus (SLE) have provided support for their cross-sectional validity in SLE. We estimated responsiveness to change, meaningful changes (minimally important differences [MIDs]), and the patient acceptable symptom state (PASS) for five PROMIS short forms to facilitate longitudinal use and interpretation of PROMIS scales in SLE.

Methods: Data from five administrations of PROMIS short forms in the FORWARD SLE cohorts were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957915PMC
January 2020